rabbit polyclonal anti p2y6r  (Alomone Labs)

Journal: Scientific Reports

Article Title: Uracil as a biomarker for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell carcinoma

doi: 10.1038/s41598-024-62434-z

Figure Lengend Snippet: Expression patterns of CD39, CD73, and P2Y6 receptor. ( A , B ) CD39 was significantly upregulated in the TME. Neither the tumor cells nor the normal epithelium was CD39 + according to IHC. ( C ) RNA-Seq data demonstrated significant upregulation of the CD39-encoding gene, ENTPD1 , in tumors ( P = 6e -4 ; n = 46). ( D ) IHC scoring confirmed CD39 enrichment in node-positive cases ( P = 3.9e -6 ; n = 23). ( E ) IHC studies demonstrated CD73 over expression in the tumor stroma, while CD73 was not expressed in the tumor region. ( F ) RNA-Seq data showing expression of the gene encoding CD73, NT5E , solely in the stroma ( P = 3.5e -6 ; n = 46). ( G ) CD73 score did not differ significantly according to the node status (n = 23). ( H ) The GPCR membrane protein, P2Y6 receptor was widely distributed within the stroma and was prominent in the invasive tumor margins, whereas distant tumor cells were P2Y6 receptor-negative. ( I ) TheP2Y6 receptor gene, P2RY6, was upregulated in tumor samples ( P = 1.05e -13 ; n = 46). ( J ) A proportional increase in P2Y6 receptor protein was observed in node-positive cases ( P = 0.05; n = 23). ( K ) ( a ) P2Y6 receptor was expressed at higher levels in immune cells compared with tumor cells. ( b ) Immune cells from node-positive cases showed higher P2Y6 receptor expression than node-negative immune cells. ( c ) In node-negative cases, P2Y6 receptor was more widely distributed in immune cells, but more widely distributed in tumor cells in node positive-cases.

Article Snippet: The selected markers were detected using the following antibodies: CD39 (Abcam Cat. No. ab223842, clone EPR20627; rabbit monoclonal; 1:500 dilution; control—human colon carcinoma), CD73 (Abcam Cat. No. ab133582, clone EPR6114; rabbit monoclonal; 1:100 dilution; control—human tonsil tissue), P2Y6 receptor (Abcam Cat. No. ab92504, clone EPR3816; rabbit monoclonal; 1:200 dilution; control– human tonsil tissue), ENTPD4 (Sigma-Aldrich Cat. No. HPA017655, rabbit polyclonal; 1:100 dilution; control—human kidney tissue) and ENTPD5 (Abcam Cat. No. ab108603, clone: EPR3784; rabbit monoclonal; 1:50 dilution; control—human kidney tissue).

Techniques: Expressing, RNA Sequencing Assay, Over Expression, Membrane

Journal: Scientific Reports

Article Title: Uracil as a biomarker for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell carcinoma

doi: 10.1038/s41598-024-62434-z

Figure Lengend Snippet: Expression of other UDP-specific P2Y-receptor subtypes. In addition to P2RY6, other UDP-specific genes, namely ( A ) P2RY14 (P = 2.19e -4 ; n = 46) was significantly over expressed in normal tissue. ( B ) P2RY2 , and ( C ) P2RY4 ,were expressed at levels that were insufficient to participate in UDP accumulation.

Article Snippet: The selected markers were detected using the following antibodies: CD39 (Abcam Cat. No. ab223842, clone EPR20627; rabbit monoclonal; 1:500 dilution; control—human colon carcinoma), CD73 (Abcam Cat. No. ab133582, clone EPR6114; rabbit monoclonal; 1:100 dilution; control—human tonsil tissue), P2Y6 receptor (Abcam Cat. No. ab92504, clone EPR3816; rabbit monoclonal; 1:200 dilution; control– human tonsil tissue), ENTPD4 (Sigma-Aldrich Cat. No. HPA017655, rabbit polyclonal; 1:100 dilution; control—human kidney tissue) and ENTPD5 (Abcam Cat. No. ab108603, clone: EPR3784; rabbit monoclonal; 1:50 dilution; control—human kidney tissue).

Techniques: Expressing

Journal: Scientific Reports

Article Title: Uracil as a biomarker for spatial pyrimidine metabolism in the development of gingivobuccal oral squamous cell carcinoma

doi: 10.1038/s41598-024-62434-z

Figure Lengend Snippet: UDP endocytosis and UMP production. (A) IHC staining showing cytoplasmic expression of P2Y6 receptor both in the tumor and stroma (mainly at the invasive tumor margins);100 × magnification. ( B , C ) IHC staining showing over expression of the UDP-specific ENTPD4 in the stroma compared to the tumor region, and significant expression of ENTPD4 in the tumor compared to the normal epithelium. ( D ) Node-negative cases showed higher expression of ENTPD4 than node-positive cases. ( E ) Immune cells expressed significantly higher levels of ENTPD4 compared to tumor cells, while ENTPD4 expression was consistent in tumor cells, irrespective of nodal status. ( F ) RNA-Seq data demonstrating higher ENTPD4 expression the tumor samples compared with normal samples ( P = 0.01; n = 46). ( G – J ) IHC staining showing exclusive expression of ENTPD5 in the tumor. ENTPD5 was expressed at higher levels in node-positive cases, although the overall expression of the ENTPD5 gene was similar in normal and tumor samples.

Article Snippet: The selected markers were detected using the following antibodies: CD39 (Abcam Cat. No. ab223842, clone EPR20627; rabbit monoclonal; 1:500 dilution; control—human colon carcinoma), CD73 (Abcam Cat. No. ab133582, clone EPR6114; rabbit monoclonal; 1:100 dilution; control—human tonsil tissue), P2Y6 receptor (Abcam Cat. No. ab92504, clone EPR3816; rabbit monoclonal; 1:200 dilution; control– human tonsil tissue), ENTPD4 (Sigma-Aldrich Cat. No. HPA017655, rabbit polyclonal; 1:100 dilution; control—human kidney tissue) and ENTPD5 (Abcam Cat. No. ab108603, clone: EPR3784; rabbit monoclonal; 1:50 dilution; control—human kidney tissue).

Techniques: Immunohistochemistry, Expressing, Over Expression, RNA Sequencing Assay